Despite recent developments and treatment successes, the outcome, and prognosis of patients with lupus nephritis (LuN) have not greatly changed since the 1980s. This review covers the application of new concepts to the understanding of renal inflammation and the study of new pharmacologic agents to improve patient outcomes.
INTRODUCTION
Lupus nephritis (LuN) is the most common severe manifestation of systemic lupus erythematosus (SLE) [1, 2] and contributes significantly to mortality in this disease [3] [4] [5] . Up to 50% of SLE patients develop LuN, which usually requires potentially toxic immunosuppressive therapies [6] [7] [8] . Despite currently available aggressive treatments, up to 50% of patients progress to end-stage renal disease (ESRD) within 5 years of diagnosis [9] [10] [11] . This response rate has not significantly improved since the 1980s, despite the advent of new therapies [8, 12, 13] . This review focuses on available therapies as well as those undergoing current clinical trial investigation. In addition, an overview of the inflammatory responses, characterizing human LuN, is provided. selection of a therapy regimen, and duration of treatment are dependent on the characterization of renal involvement based on the 2003 International Society of Nephrology/Renal Pathology Society classification criteria (Table 1 ) [16] .
In clinical practice, human lupus glomerulonephritis is treated with a regimen of induction therapy followed by additional maintenance immunosuppression. Many of the treatments under discussion in this review have not received either the US or European regulatory agency approvals for the indication of LuN therapy and their use should be considered as off-label or investigational (Food and Drug Administration and European Medicines Agency, respectively). Traditional regimens are based on the National Institutes of Health (NIH) trials, which found that glucocorticoids and intravenous pulse cyclophosphamide (CYC) were more effective than glucocorticoids alone in LuN (all classes) [12] . There are also data supporting low-dose pulse intravenous CYC based on the Euro-Lupus regimen where patients receive intravenous CYC 500 mg every 2 weeks for six doses [17, 18] . Mycophenolate mofetil (MMF) is another recognized option for induction therapy. Multiple trials have demonstrated that MMF has comparable efficacy with CYC [8, 19] . Additionally, in black/mixedrace patients, MMF showed higher response rates compared with intravenous CYC (60.4 vs. 38.5%, P ¼ 0.033) [8] .
After completion of initial induction therapy, maintenance therapy is generally indicated in all patients. Studies [20, 21] have shown that patients who are not placed on maintenance immunosuppressive therapy are at increased risk of worsening renal function, ESRD, and even death. The Aspreva Lupus Management Study [22] found treatment failure, renal flares, and time-to-rescue therapy were all significantly higher utilizing azathioprine (AZA) as compared with MMF for this indication. Conversely, the MAINTAIN trial (LuN class III/IV/V) [23] found similar rates of renal flares and these findings were maintained at 10-year follow-up [24 && ]. The optimal duration maintenance therapy with either agent is not clear at present. The Randomized MMF Withdrawal in Systemic Lupus Erythematosus trial (Clinicaltrials. gov identifier: NCT01946880) is a multicenter randomized controlled trial (RCT), investigating the effects of MMF withdrawal in clinically stable SLE patients that is currently ongoing to help answer this important clinical question.
Uncomplicated class V LuN is currently treated as a special subset with different treatment recommendations based on published trials [25, 26] . The ACR and EULAR both currently recommend prednisone and MMF for induction in patients with isolated class V involvement [14, 15] .
As noted in the above discussion, despite current therapies, a significant proportion of patients with LuN develop ESRD. Therefore, there is an unmet need for novel therapies [11, [27] [28] [29] . Tacrolimus has been studied as a potential alternative for induction therapy. Chen et al. [30] 
KEY POINTS
The clinical approach to LuN patient management centers predominantly on glomerular pathology.
The optimal duration of maintenance therapy for LuN is currently unknown.
TII is an important determinant in at least a subset of patients and is tied to faster disease progression to ESRD.
The inflammatory infiltrate possess features of deregulated adaptive and innate immune responses, the future study of which may reveal important clues to prognosis and future therapy development. Given their success in other rheumatic diseases, biologic therapies have also been studied as potential treatments for LuN. Rituximab (RTX), which targets CD20 expressed on B cells, has been shown to be beneficial in multiple small open-label and retrospective studies [34] [35] [36] [37] [38] [39] . Despite these encouraging results, Lupus Nephritis Assessment With Rituximab (LUNAR) -a phase III RCT [40] -produced contradictory results. This trial included 144 patients with class III/IV AE V LuN treated with either RTX or placebo and MMF and glucocorticoids. At 52 weeks there was no difference in CR or partial response (PR) rates in the RTX vs. placebo groups (56.9 vs. 45.8%, P ¼ 0.18). In a subgroup analysis, black patients in the RTX group were found to have a trend to higher overall response rates (overall response: combined PR and CR) compared with placebo (70 vs. 45%, P ¼ 0.20).
Despite LUNAR studies have continued to investigate the potential use of RTX in LuN. Moroni et al. performed a clinical observational study of 54 patients with class III/IV/V LuN induced with either RTX, MMF, or CYC [41] . At 3 months, renal response rates were similar among the three groups (58.8 RTX vs. 63.1 CYC vs. 64.7% MMF). At 12 months, CR rates were also similar between the groups (70.6 RTX vs. 65 CYC vs. 52.9% MMF). Although this was a small, noncontrolled trial, it suggests that RTX may still be beneficial in selected LuN patients.
Belimumab, which inhibits B-cell activating factor (BAFF), is a Food and Drug Administrationapproved agent for treating nonrenal SLE that is also being studied as a potential therapy for LuN. The Study of Belimumab in Subjects With Systemic Lupus Erythematosus (BLISS)-52 [42] and BLISS-76 [43] trials focused on stable, nonsevere LuN and excluded patients with acute and/or severe LuN defined as proteinuria at least 6 g/day, serum creatinine more than 2.5, or those on dialysis. In a pooled analysis Dooley et al. [44] found that although patients receiving belimumab 1 or 10 mg/kg had decreased proteinuria compared with placebo, this difference did not meet clinical significance (median decrease: 48.3/39.1 vs. 75.2%, NS). Similarly, there was no significant difference in renal flare (2.1/1.1 vs. 3%, NS) and renal remission rates (65.7/70.5 vs. 58.7%, NS) as compared with placebo. Despite this, renal improvement as measured by Safety of Estrogens in Lupus Erythematosus National Assessment trial SLE disease activity index [45] was statistically significant in patients being treated concurrently with MMF and belimumab 1 and 10 mg/kg groups compared with placebo (52.6/63.2 vs. 27.8%, P ¼ 0.03). Although these studies only included patients with stable, nonsevere LuN, they suggest that belimumab may be beneficial. There is a current phase III, double-blinded RCT investigating the effects/safety of standard of care and belimumab 10 mg/kg vs. placebo in patients with LuN to address this question (Clinicaltrials.gov identifier: NCT01639339).
Another candidate biologic therapy for LuN is abatacept, which is a soluble fusion protein of cytotoxic T lymphocyte-associated antigen 4 and Fc immunoblobulin IgG1. Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis randomized patients with class III/IV AE V LuN to weight-based intravenous abatacept vs. placebo [46] . Both groups also received glucocorticoids and 500 mg intravenous CYC every 2 weeks for six doses, followed by AZA maintenance. At 24 weeks, there was no difference in CR or overall response rates in the abatacept vs. placebo groups (33 vs. 31% CR, 59 vs. 59% overall response). Adverse events were comparable in both groups. Studies have also looked at combination of abatacept and MMF. A double-blind study [47] randomized patients with class III/IV AE V LuN to intravenous abatacept 30 mg/ kg through day 57, then 10 vs. 10 mg/kg vs. placebo. Patients were also maintained on MMF and glucocorticoids. Investigators found no difference between placebo and abatacept in regards to patients who met criteria for CR or PR. There is a current ongoing phase III, double-blind multicenter RCT investigating abatacept vs. placebo with background MMF and glucocorticoids over a 104-week period. The primary efficacy endpoint is the proportion of patients attaining CR based on renal function, proteinuria, urine sediment, and glucocorticoids dose (Clinicaltrials.gov identifier: NCT01714817).
There have been several other recent studies evaluating novel treatments for proliferative LuN, which were terminated early because of side-effects or inefficacy. Atacicept is a soluble, fully human, recombinant fusion protein, which inhibits both BAFF and a proliferation-inducing ligand (APRIL) [48] . A phase II/III double-blind RCT of subcutaneous atacicept (four patients) or placebo (two patients) and MMF and prednisone for active class III/IV LuN was discontinued early because of severe rapid declines in serum IgG and serious infections in three out of four treated patients [49] . Ocrelizumab, a recombinant humanized antibody, sharing targeting of CD20 with rituximab [50] , was also studied in a double-blind phase III RCT of 381 patients with class III/IV AE V LuN [51] . The study was also terminated early because of increased risk of serious infections (28.3% overall) in the ocrelizumab group. The long-term extension trial of BIIB023, a humanized monoclonal antibody against TNF-related weak induced of apoptosis (TWEAK), in class III/ IV AE V disease was also recently terminated because of inefficacy (Clinicaltrials.gov identifier: NCT01930890).
Of the possible new therapies undergoing current development, blisibimod is a BAFF antagonist that binds to both soluble and membrane-bound BAFF and inhibits the interaction of BAFF with BAFF receptor, transmembrane activator and Calcium modulating ligand interactor (TACI), and B-cell maturation antigen [52] . A recent double-blind phase Ia/Ib RCT of 56/64 patients with mild/inactive lupus were randomized to receive either blisibimod subcutaneous/intravenous, respectively, at various doses vs. placebo [53] . The trial found a significant decrease in patient serum B-cell counts with the study drug without an increase in adverse events. Although this trial excluded patients with active LuN, there is a pending phase III, double-blind RCT to evaluate the efficacy and safety of blisibimod in patients with lupus and stable LuN (Clinicaltrials.gov identifier: NCT02514967).
Mizoribine (MIZ) is another potential novel treatment for LuN. It is thought to inhibit inosine monophosphate dehydrogenase -the same target as MMF [54] . Feng et al. [55] randomized 90 Chinese patients with active class III/IV/V LuN to receive MIZ every other day vs. MMF vs. intravenous CYC 500 mg every 2 weeks and glucocorticoids over a 24-week period. All three groups showed an improvement in renal responses at 12 weeks but the CYC group had more early responders compared with MIZ (96.7 vs. 73.3%, P ¼ 0.02). At 24 weeks, CR and overall response rates were similar between all groups (CR -22.7 MIZ, 24 MMF, and 25% CYC, overall response -68.2, 72, and 75%). An ongoing phase III noninferiority RCT is actively recruiting patients in China to further investigate the role of MIZ vs. CYC in class III/IV/V LuN (Clinicaltrials.gov identifier: NCT02256150). IFN1, including IFNa, have been implicated in the pathogenesis of SLE. Anifrolumab, a human monoclonal antibody against the INFa receptor 1 [56] , is currently being studied as a potential new therapy for lupus. A phase II open-label trial in 17 Japanese patients with SLE showed that anifrolumab suppressed interferon gene signatures in 85% of patients at the 300 mg dose at day 169 and 95% of patients in the 1000 mg dose at day 85 without any safety signals [57] . The Treatment of Uncontrolled Lupus via the Interferon Pathway -Lupus Nephritis trial is a phase II double-blind RCT, which is currently enrolling patients to study the efficacy and safety of anifrolumab vs. placebo in class III/IV AE V LuN (Clinicaltrials.gov identifier: NCT02547922).
Finally, laquinimod (LAQ) is another promising novel therapy for LuN. LAQ's method of action is not fully known but it is thought to behave as an oral immunomodulatory agent by downregulating selected cytokines, including IL-6, IL-12, IL-17, IL-23, and TNFa, whereas increasing IL-10 [58] . In a phase IIa double-blind RCT of 46 LuN patients comparing LAQ 0.5 or 1 mg daily vs. placebo and MMF and glucocorticoids [58] , the investigators found that renal responses were higher in the LAQ 1 mg compared with the 0.5 mg and placebo groups (62.5 vs. 40 vs. 33.3%) at 24 weeks. The authors note they are planning a larger study to further investigate the efficacy and safety of LAQ but no formal trials have been registered at this time.
Pathophysiology and current experimental models
As previously noted, although kidney involvement in LuN can affect either glomerular or tubulointerstitial compartments as well as combinations thereof, most classification schemes utilized in clinical practice focus almost exclusively on glomerular pathology. Two other commonly used tools for assessing disease severity -the NIH activity and chronicity indices [59] -are similarly heavily weighted toward glomerular, as opposed to tubulointerstitial, involvement ( Table 2 ) Moreover, fibrosis and sclerosis generally contribute more to the above scoring system than inflammation in either glomerular or tubulointerstitial compartments ( Table 2) [60] . A growing body of published literature supports the importance of tubulointerstitial inflammation (TII) in determining prognosis and patient outcomes [61] [62] [63] [64] [65] . Although these studies noted an association of active TII with glomerular involvement, a multivariate analysis, performed in a large retrospective cohort of 59 LuN patients, noted that TII was an independent predictor of ESRD progression and this correlated with serum creatinine level at time of biopsy (odds ratio 2.4, 95% confidence interval 1.4, 4.3, P ¼ 0.002 for GFR < 60 ml/min) [60] . Interestingly, in contrast to most current mouse models of lupus and glomerulonephritis, TII has not been shown to be related to levels of complement, double-stranded DNA (dsDNA), or other serum autoantibodies [60, 63] .
Further studies [66] [67] [68] of TII in animal models have been complicated by an absence of an adequate experimental model that fully recapitulates the spectrum of tubulointerstitial involvement seen in human patients, such as germinal center formation and other features of tertiary lymphoid neogenesis. To date, characterization of TII in humans has revealed the following common features: the presence of widely interspersed B cells and plasma cells, notably absent from glomeruli [60, 66] ; colocalization of B and T cells in well formed aggregates in a majority of biopsy specimens [66] ; occurrence of discrete immune-complex deposits within the tubular basement membrane in 50% of patients [66, 69] ; and the presence of T follicular-helper (T FH ) cells in close conjugates with B cells in a significant fraction of patients, which correlated with worse renal function at time of biopsy in a retrospective analysis [mean serum creatinine/GFR by Modification of Diet in Renal Disease: 2.3/44.8 ml/min for T FH þ biopsy (n ¼ 19) and 1.1/74.8 ml/min, for T FH biopsy (n ¼ 23) patients, respectively; P ¼ 0.03] [70] . The adaptive nature of the inflammatory response in TII has been further evidenced by clonal relatedness of B-cell antibodies, expressed from patient biopsies [66] . Analysis of the most common antibody specificities has failed to reveal in-situ responses to common nuclear antigens such as dsDNA but instead had predominantly cytoplasmic reactivity (11 of 25 expressed antibodies) [71] . The majority of these (10 of 11) were recently shown to bind to vimentinan intermediate filament that is a common structural component of cells [4] . In addition, many of the expressed antibodies displayed a degree of polyreactivity and rheumatoid factor activity -a measure that may reflect the in-situ selection environment. Of interest, high titers of these antibodies were almost exclusively seen in biopsies with the highest degree of TII. Anti-vimentin antibodies have been previously described in instances of allograft rejection with high titers predictive of graft failure, and vimentin immunization of a mouse model led to accelerated cardiac rejection [72] [73] [74] [75] . As such, an anti-vimentin response is unlikely to be specific for lupus but may reflect a general state of deregulated self-tolerance mechanisms in the context of inflammation. An intriguing possibility is whether measurement of anti-vimentin antibodies would be useful as a clinical biomarker of assessing the degree of TII involvement. To date, only anti-C1q antibodies have been prospectively validated to distinguish proliferative from nonproliferating nephritis in human patients but have not been shown to be predictive of clinical course [76 && ]. Apart from the attention paid to features of adaptive immunity in the context of TII, the study of mediators of innate inflammatory responses are also likely to be of great importance. The vast majority of antigen-presenting cells in the kidney are not limited to B cells [77] . The cortex of normal human kidneys contains a network of myeloid dendritic cells as well as fewer numbers of plasmacytoid dendritic cells (pDCs) [78] . It also contains macrophages that have similar surface phenotypes, and possibly functions, as dendritic cells [79] . In murine models, these populations appear to actively maintain tolerance in normal tissue, limit inflammation in response to tissue damage [80] [81] [82] [83] , drive inflammation in response to ischemia, infection and ureteral obstruction [80, [84] [85] [86] , and resolve inflammation to allow repair [87, 88] . In New Zealand Black/New Zealand White mice, kidneys are infiltrated with proinflammatory macrophages and dendritic cells [89] , and both human and murine lupus is associated with a pattern of in-situ mRNA expression, indicative of activated antigenpresenting cells [90] . Histologically, human LuN is associated with increased dendritic-cell infiltration and chemokine expression. An increase in the pDC:myeloid dendritic cells ratio has been associated with more severe glomerulonephritis [91, 92] .
As innate immune responses have previously been more difficult to target therapeutically, this will be an important area of future study. The recent arrival of targeted immunotherapies such as programmed death ligand-1 blockade [93] may bring about an important revolution in this previously neglected area of treatment of innate-mediated autoimmunity.
A final example of the potential for cooperation between aberrant innate and adaptive responses can be seen in a recent publication, implicating the surprising role of IgE anti-dsDNA antibodies in LuN [94 & ]. In this study, the addition of minute quantities of IgE anti-dsDNA antibodies to IgG antibodies with the same specificity was shown to have a potent synergistic effect on pDC production of IFNa. The prevalence of anti-dsDNA IgE antibodies in SLE patients was noted to be markedly elevated as compared with healthy controls and patients with atopic dermatitis [95] [96] [97] . The authors propose that IgE serves to synergize with and amplify the response to IgG autoantibodies in an interferondependent manner. Indeed, the presence of significant IgE antibody deposits in glomeruli and tubulointerstitium was noted in a majority of biopsies studied, where they colocalized with pDCs, displaying an activated IFN1 signature. In support of the hypothesis of a potential amplification loop of aberrant in-situ responses, the addition of IgE anti-dsDNA antibodies to in-vitro pDC : B-cell cultures leads to the marked proliferation of B cells, plasma cells, and production of IgM. These data reveal a potential novel mechanism, whereby coordination between the adaptive and innate arms of the immune response creates self-reinforcing pathogenic circuits. They also argue that elucidating precise pathogenic mechanisms is a critical first step in developing appropriate targeted therapies.
CONCLUSION
Although great strides have been made in treating human LuN, a significant percentage of patients still progress to chronic kidney disease and ESRD with conventional treatments. Although ACR and EULAR recommendations [14, 15] provide some guidance on traditional induction and maintenance regimens, given the high numbers of LuN patients who do not achieve complete remission with these therapies, current approaches may not be optimal for all patients. Although clinical trials attempt to recruit ethnically diverse patient cohorts, no large RCT to date have been powered to definitively show the superiority of one regimen over another in a particular patient subgroup. Additionally, there is little guidance on how to proceed in patients who are refractory to conventional therapies. Insights into the pathogenesis of LuN and, particularly, the contributions of innate and adaptive arms of the immune system in the context of TII may become increasingly important in approaching patients with a poor prognosis. The development of an animal model, able to reliably recapitulate the full breadth of human LuN, would represent an important interim step in the development and preclinical validation of appropriate therapeutic targets. In addition to developing new therapeutic agents, future prospective clinical trials need to take TII into consideration as both an important prognostic marker and a central pathogenic mechanism.
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